➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Moodys
Johnson and Johnson
Medtronic
McKinsey

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ORACEA

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Oracea

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00892281 ORCA - Oracea® for Rosacea: A Community-based Assessment Completed Galderma Laboratories, L.P. Phase 4 2009-04-01 The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
NCT01308619 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed Galderma Laboratories, L.P. Phase 4 2011-04-01 The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
NCT01426269 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Completed Galderma Laboratories, L.P. Phase 4 2011-09-01 The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
NCT01782989 Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) Recruiting MEDARVA Foundation Phase 2/Phase 3 2013-02-01 This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).
NCT01782989 Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) Recruiting Paul Yates, MD, PhD Phase 2/Phase 3 2013-02-01 This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).
NCT01872715 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed Galderma Laboratories, L.P. Phase 4 2013-03-01 The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
NCT03075891 Oracea Soolantra Association in Patients With Severe Rosacea Recruiting Galderma Phase 4 2017-07-05 The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of severe Rosacea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oracea

Condition Name

Condition Name for Oracea
Intervention Trials
Rosacea 4
Papulopustular Rosacea 1
Geographic Atrophy 1
Central Centrifugal Cicatricial Alopecia (CCCA) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oracea
Intervention Trials
Rosacea 5
Macular Degeneration 1
Geographic Atrophy 1
Atrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oracea

Trials by Country

Trials by Country for Oracea
Location Trials
United States 46
Canada 1
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oracea
Location Trials
Kentucky 5
California 4
Texas 4
Florida 3
Oregon 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oracea

Clinical Trial Phase

Clinical Trial Phase for Oracea
Clinical Trial Phase Trials
Phase 4 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oracea
Clinical Trial Phase Trials
Completed 4
Recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oracea

Sponsor Name

Sponsor Name for Oracea
Sponsor Trials
Galderma Laboratories, L.P. 4
Galderma 1
Paul Yates, MD, PhD 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oracea
Sponsor Trials
Other 5
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Moodys
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.